A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or Obese
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Basic science
Enrollment
82actual
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-28 | actual | When the study began enrolling |
| Primary completion | 2025-03-16 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-04-14 | actual | The whole study's end, after follow-up |
| First posted | 2024-08-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Obesity
Interventions
- Drug: Danuglipron — also filed as PF-06882961
- Drug: Atorvastatin
- Drug: Rosuvastatin
Primary outcomes
what the primary-completion date above is the date OFSteady-state area under the concentration-time profile from time zero to 24 hours (AUC24) for danuglipron
measured Predose to 24 hours post danuglipron administration
Steady-state maximum observed concentration (Cmax) for danuglipron
measured Predose to 24 hours post danuglipron administration
Steady-state time to reach maximum observed concentration (Tmax) for danuglipron
measured Predose to 24 hours post danuglipron administration
Area under the concentration-time curve from time zero extrapolated to infinite time (AUCinf), as data permit, for atorvastatin
measured Predose to 72 hours post atorvastatin administration
Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) for atorvastatin (only if AUCinf is not reportable)
measured Predose to 72 hours post atorvastatin administration
Area under the concentration-time curve from time zero extrapolated to infinite time (AUCinf), as data permit, for rosuvastatin
measured Predose to 96 hours post rosuvastatin administration
Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) for rosuvastatin (only if AUCinf is not reportable)
measured Predose to 96 hours post rosuvastatin administration
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed